Skin Diseases  >>  Xolair (omalizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xolair (omalizumab) / Roche, Novartis
OXAD, NCT01678092: Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

Completed
1
8
US
omalizumab
Stanford University
Atopic Dermatitis
12/06
12/06
NCT01544348: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Completed
1
295
US
Placebo, Omalizumab, Xolair, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
MedImmune LLC
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
06/13
06/13

Download Options